Filtered By:
Condition: Heart Attack
Nutrition: Sodium
This page shows you your search results in order of date.
Order by Relevance | Date
Total 261 results found since Jan 2013.
How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you…
Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China.
I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1
We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004.
Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news
Sodium-Glucose Cotransporter-2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta-Analysis of Randomized Trials and Systematic Review
Conclusions SGLT2 inhibitors significantly reduced atherosclerotic MACEs in subjects having both chronic kidney disease and type 2 diabetes without established ASCVD.PMID:37581396 | DOI:10.1161/JAHA.123.030578
Source: Atherosclerosis - August 15, 2023 Category: Cardiology Authors: Hammad Rahman Safi U Khan Ahmad N Lone Priyanka Ghosh Mahathi Kunduru Saurabh Sharma Sudhakar Sattur Edo Kaluski Source Type: research
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study
CONCLUSION: Among patients with gout, SGLT2is may reduce recurrent flares and gout-primary ED visits and hospitalizations and may provide cardiovascular benefits.PRIMARY FUNDING SOURCE: National Institute of Arthritis and Musculoskeletal and Skin Diseases.PMID:37487215 | DOI:10.7326/M23-0724
Source: Annals of Internal Medicine - July 24, 2023 Category: Internal Medicine Authors: Natalie McCormick Chio Yokose Jie Wei Na Lu Deborah J Wexler J Antonio Avi ña-Zubieta Mary A De Vera Yuqing Zhang Hyon K Choi Source Type: research
Differential Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular and Renal Outcomes According to Renal Function: A Dose-Response Meta-Analysis Involving 10 Randomized Clinical Trials and 71,553 Individuals
CONCLUSION: The protective effects of SGLT2i for reducing most adverse cardiovascular and renal outcomes persisted in patients with variable degrees of renal impairment. The observed benefits such as preventing CV death, HF worsening, or stroke may be greater for patients with more severe CKD. Considering the cardiovascular and renal benefits associated with SGLT2i treatment, patients with CKD should be treated aggressively to improve outcomes.PROSPERO REGISTRATION NUMBER: CRD42021273500.PMID:37474112 | DOI:10.1093/ejendo/lvad078
Source: European Journal of Endocrinology - July 20, 2023 Category: Endocrinology Authors: Donna Shu-Han Lin An-Li Yu Hao-Yun Lo Cheng-Wei Lien Jen-Kuang Lee Fu-Tien Chiang Yu-Kang Tu Source Type: research
Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis
ConclusionIn patients with type 2 diabetes, the hypotensive effects of SGLT2i and GLP-1 RAs were significantly associated with a reduction in mortality and cardiorenal events. These findings suggest that the lowering BP effect could be seen as an additive indicator of cardiovascular protection by SGLT2i and GLP-1 RAs drugs.
Source: Acta Diabetologica - July 13, 2023 Category: Endocrinology Source Type: research
Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3)
This study is a multicentre, randomised, double-blind, placebo-controlled trial. Patients with T2DM who fulfilled the inclusion criteria were randomly divided to receive weekly administration of either PEG-Loxe 0.2 mg or placebo (1:1 ratio). The randomisation was stratified according to utilisation of sodium-glucose cotransporter 2 inhibitors, history of CV disease and body mass index. The research period is expected to be 3 years, with a 1-year recruitment period and a 2-year follow-up period. The primary outcome is the occurrence of the first MACE, described as CV death, non-fatal myocardial infarction or non-fatal strok...
Source: BMJ Open - May 16, 2023 Category: General Medicine Authors: Xie, Y., Kuang, J., Li, Q., Hong, T., Ji, L., Kong, Y., Duan, Y., Chen, L. Tags: Open access, Diabetes and Endocrinology Source Type: research
Billions With Nutrition Deficiency!?
Almost no one gets enough selenium. Officially, at least a billion — with a B — people have a selenium deficiency.1
But I suspect the numbers are much higher than that.
You can’t get enough selenium from food alone anymore. That’s true even if you eat a healthy, varied diet. And you can thank Big Agra for that.
With their harsh pesticides, synthetic fertilizers, and single-crop strategy, these massive farms have stripped the nutrients out of the soil. No nutrients in the soil mean no nutrients in the food.
All of this makes it difficult — if not impossible — to get even some of the daily selenium you need to ...
Source: Al Sears, MD Natural Remedies - May 15, 2023 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Nutrition Source Type: news
Effect of sodium bicarbonate on cardiovascular outcome and mortality in patients with advanced chronic kidney disease
Conclusion: The cohort study found that in real world practice, among patients with
advanced CKD stage V, use of sodium bicarbonate was associated with similar risk of
dialysis compared with non-users, Nonetheless, use of sodium bicarbonate was
associated with significantly lower rate of MACE and mortality. The study results
reinforced the benefits of sodium bicarbonate therapy in the expanding CKD
population. Further prospective studies are needed to confirm these findings.
Source: Frontiers in Pharmacology - May 11, 2023 Category: Drugs & Pharmacology Source Type: research
Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
CONCLUSION: The addition of GLP1RA was associated with primary reductions of MACE and HF hospitalization compared with DPP4i use; SGLT2i addition was not associated with primary MACE prevention.PRIMARY FUNDING SOURCE: VA Clinical Science Research and Development and supported in part by the Centers for Diabetes Translation Research.PMID:37155984 | DOI:10.7326/M22-2751
Source: Annals of Internal Medicine - May 8, 2023 Category: Internal Medicine Authors: Tadarro L Richardson Alese E Halvorson Amber J Hackstadt Adriana M Hung Robert Greevy Carlos G Grijalva Tom A Elasy Christianne L Roumie Source Type: research
